Substituted N-Hexanoic Peptide Analogues for GI Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds with neuroprotective and neuroregenerative properties, such as N-hexanoic-L-tyrosine-L-isoleucine-(6)-aminohexanoic amide, face challenges with optimized pharmacokinetic and pharmacodynamic properties, particularly in simulated gastrointestinal conditions and plasma stability.
Innovation Solution
Synthesis of compounds with a di-amino acid core structure, substituted by organic functional groups at the C-terminus, N-terminus, and/or side-chain, which are stable in simulated intestinal and gastric fluids but hydrolyze in plasma to release the active Base Structure or similar compounds, maintaining therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the Base Structure compound is used directly, then it shows neuroprotective and neuroregenerative activity, but it has poor stability in simulated gastrointestinal fluids and plasma
Solution Approach 1:
The patent applies preliminary action by designing prodrug compounds that are pre-modified with protecting groups or bioisosteric replacements before administration. These modifications are performed in advance to prevent degradation in gastrointestinal fluids and plasma, ensuring the compound reaches its target intact while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses intermediary compounds (prodrugs) as mediators between the unstable Base Structure and the biological system. These intermediary compounds possess improved stability in gastrointestinal fluids and plasma, yet can be converted to the active Base Structure in vivo, thus bridging the gap between stability requirements and therapeutic efficacy.
2Stability of the object's composition
If the compound is made more stable through chemical modification, then stability in gastrointestinal fluids improves, but the compound must still hydrolyze in plasma to release active form
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific locations on the molecule (such as the amide bond region) rather than throughout the entire structure. This allows the compound to gain stability in gastrointestinal fluids through localized bioisosteric replacements or protecting groups, while maintaining the overall molecular simplicity and enabling plasma hydrolysis to release the active form.
3Reliability
If substituted analogues are synthesized to improve pharmacokinetic properties, then stability increases, but synthesis complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying specific molecular parameters (such as replacing the amide oxygen with CH2, or substituting amino acid side chains) to improve pharmacokinetic properties including stability in gastrointestinal fluids and plasma. These controlled parameter changes allow for methodical optimization of drug properties while managing synthesis complexity through focused modifications rather than comprehensive structural redesign.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized compounds demonstrate increased stability in gastrointestinal conditions and effective conversion to active forms in plasma, ensuring sustained therapeutic efficacy for neurodegenerative diseases and traumatic injuries.
Implementation Method 1
can be hydrolyzed in plasma to produce Base Structure or Base Structure-like compounds
Data Source
AI summary
The present technology relates to compounds, kits, compositions, and methods useful for the treatment of numerous pathologies including dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, defective wound healing, and/or sensorineural hearing and vision loss.